Cargando…
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Autores principales: | Selby, Mark J., Engelhardt, John J., Johnston, Robert J., Lu, Li-Sheng, Han, Minhua, Thudium, Kent, Yao, Dapeng, Quigley, Michael, Valle, Jose, Wang, Changyu, Chen, Bing, Cardarelli, Pina M., Blanset, Diann, Korman, Alan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115859/ https://www.ncbi.nlm.nih.gov/pubmed/27861630 http://dx.doi.org/10.1371/journal.pone.0167251 |
Ejemplares similares
-
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
por: Selby, Mark J., et al.
Publicado: (2016) -
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
por: Thudium, Kent, et al.
Publicado: (2022) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022) -
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)